Asymptomatic Colon Cancer Research Articles

The Evaluation of Methylated Septin 9 in Blood Plasma and Tissue Biopsies for the Early Detection for Asymptomatic Colon Cancer

The purpose of this study was to assess the utility of the SEPT9 genetic marker in the early detection of colon cancer patients. A case-control study was conducted on forty newly diagnosed colon cancer patients. The study was done between March 2019 and January 2020, patients from the Gastroenterology and Liver Education Hospital, Al-imamain Al-Kadhimain Medical City, and Baghdad Teaching Hospital were recruited. Colon cancer patients' mean age ± standard deviation was 54.4 ± 10.79 years while the age ± standard deviation of the mean of the control group was 55.1±8.54 years. For septin9 tissue methylation of the controls was done on the non-malignant tissues of the same patients.
 This study concluded that the percentage of Septin 9 (SEPT9) in the tissue of patients with colon cancer (CC) was the highest value, which is more significant than that of the serum of CC patients. Both of these groups were significantly higher than the percentage of SEPT9 methylation of control tissue and serum.
 Non-significant differences were obtained in the levels of CEA and CA19-9 between CC patients and controls.

Symptomatic and Asymptomatic Colon Cancer Recurrence: A Multicenter Cohort Study.

Follow-up after colorectal cancer treatment with curative intent aims to detect recurrences and metachronous tumors in a timely manner. The objective of this study is to assess how recurrent disease presents and is diagnosed within scheduled follow-up according to the national guideline for the Netherlands. In a retrospective study of consecutive patients with colorectal cancer who were treated in 2 hospitals in the Netherlands, we identified patients with colon cancer who underwent surgery with curative intent between January 2007 and December 2012. Patients who developed recurrent disease were included for further analyses. From a total of 446 patients who were been treated for colon carcinoma with curative intent, 74 developed recurrent disease (17%). In 43 of those patients (58%), recurrent disease was detected during a scheduled follow-up visit, with 41 (95%) being asymptomatic. Tumor marker testing, imaging, and colonoscopy identified all of these recurrences. In the remaining 31 patients with recurrent disease (42%), recurrence was found during non-scheduled interval visits; 26 (84%) of these patients were symptomatic. The most prevalent symptoms were abdominal pain, altered defecation, and weight loss. Patients with asymptomatic recurrences had a significantly higher overall survival compared with patients with symptomatic recurrences. In this cohort, 42% of the recurrences after initial curative treatment for colon cancer were found during non-scheduled interval visits, mainly based on symptoms. Primary care physicians who take care of patients whose colon cancer might recur should be aware of the relatively high rate of symptomatic recurrences and of typical presenting symptoms.

Asymptomatic colon cancer finding during open bariatric surgery in a 29-year-old female

Obesity is known as a primary condition for colon cancer development [ 1 Larsson S.C. Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007; 86: 556-565 PubMed Google Scholar , 2 Larsson S.C. Rutegård J. Bergkvist L. Wolk A. Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish men. Eur J Cancer. 2006; 42: 2590-2597 Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar , 3 Giovannucci E. Ascherio A. Rimm E.B. Colditz G.A. Stampfer M.J. Willett W.C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995; 122: 327-334 Crossref PubMed Scopus (824) Google Scholar ]. Hypochromic anemia is a frequent finding in obese patients; nonetheless, colon cancer must be suspected and excluded [ [4] Park H.W. Han S. Lee J.S. et al. Risk stratification for advanced proximal colon neoplasm and individualized endoscopic screening for colorectal cancer by a risk-scoring model. Gastrointest Endosc. 2012; 76: 818-828 Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar ]. Bariatric surgery is known as the most effective treatment for moderate and severe obesity [ [5] 2004 ASBS Consensus Conference on Surgery for Severe Obesity. Surg Obes Rel Dis 2005;1:297–381. Google Scholar ]. The authors report a case in which a colon cancer was found during bariatric surgery.

Detection of Asymptomatic Colon Cancer During Staging of Breast Cancer Patient by PET-CT

Many imaging techniques are being used for cancer scanning, staging and follow-up. Currently, PET-CT has growing popularity in staging and follow-up of most of the cancers. Secondary cancers can be incidentally detected during PET-CT evaluations. Benign findings like adenoma, fibroglandular tissue, sarcoidosis or inflammatory focus as well as a new primary cancer can be obtained by PET-CT. This case report presents detection of synchronous colon cancer in a patient with breast cancer who was referred for initial staging by PET-CT. By this way, the cancer type more effective on the survival could be treated at early stage.

Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10

Major concerns surround combining chemotherapy with bevacizumab in patients with colon cancer presenting with an asymptomatic intact primary tumor (IPT) and synchronous yet unresectable metastatic disease. Surgical resection of asymptomatic IPT is controversial. Eligibility for this prospective, multicenter phase II trial included Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1, asymptomatic IPT, and unresectable metastases. All received infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) combined with bevacizumab. The primary end point was major morbidity events, defined as surgical resection because of symptoms at or death related to the IPT. A 25% major morbidity rate was considered acceptable. Secondary end points included overall survival (OS) and minor morbidity related to IPT requiring hospitalization, transfusion, or nonsurgical intervention. Ninety patients registered between March 2006 and June 2009: 86 were eligible with follow-up, median age was 58 years, and 52% were female. Median follow-up was 20.7 months. There were 12 patients (14%) with major morbidity related to IPT: 10 required surgery (eight, obstruction; one, perforation; and one, abdominal pain), and two patients died. The 24-month cumulative incidence of major morbidity was 16.3% (95% CI, 7.6% to 25.1%). Eleven IPTs were resected without a morbidity event: eight for attempted cure and three for other reasons. Two patients had minor morbidity events only: one hospitalization and one nonsurgical intervention. Median OS was 19.9 months (95% CI, 15.0 to 27.2 months). This trial met its primary end point. Combining mFOLFOX6 with bevacizumab did not result in an unacceptable rate of obstruction, perforation, bleeding, or death related to IPT. Survival was not compromised. These patients can be spared initial noncurative resection of their asymptomatic IPT.

Carcinoma colon presenting as cutaneous metastasis to an old operative scar of hysterectomy

Cutaneous metastases from asymptomatic colonic carcinoma have been documented rarely in the literature. But cutaneous metastasis to an already present operative scar as the mode of presentation of otherwise asymptomatic colon cancer is an extremely rare phenomenon which has been described only thrice till now. We report such a case of adenocarcinoma of sigmoid colon which presented as a large subcutaneous metastasis to an already existing scar of hysterectomy.

Case Report Unsuspected and widespread colon cancer in a young woman

Liver and lung metastasis and local lymph node invasion are reported in a 26-year-old Brazilian woman with an asymptomatic colon cancer. She was admitted complaining of right upper quadrant pain, and the diagnostic procedures revealed an unsuspected adenocarcinoma (stage IV) in the descending colon. This malignancy is more frequent in patients older than 40 years, but it usually follows a more aggressive course in young people. Late detection of colon cancer usually results in worst prognosis [corrected]

An audit of the utility of in-patient fecal occult blood testing

OBJECTIVES: Recent surveys of physician practice have suggested the existence of excessive, inappropriate use of the fecal occult blood test (FOBT). We studied the implementation of this test in hospitalized patients. METHODS: We performed a retrospective chart review of 1000 randomly selected patients who had been discharged from the Medicine service at four teaching hospitals. Patient demographics, clinical presentation, presence or absence of overt GI bleeding, and use of medications that might affect the FOBT were recorded. Reviewers assessed whether patients who had FOBT would have been candidates for colon resection if asymptomatic colon cancer had been found. RESULTS: Digital rectal examination was documented in 44.8% of patients; the findings were recorded in only 9%. A total of 421 patients had FOBT on admission, usually on stool obtained at digital rectal examination. Of the patients with a positive FOBT, 17% had active GI bleeding. Only 41.1% of patients with a positive FOBT were referred to the gastroenterology service. In 70.5% of patients, FOBT could be considered inappropriate because of factors such as age, active GI bleeding, or use of aspirin or other nonsteroidal anti-inflammatory drugs. CONCLUSIONS: The FOBT, which is validated only for colorectal cancer screening, is often performed inappropriately in patients admitted to the hospital. This test should be restricted in hospital practice. It would be preferable to identify patients who are appropriate candidates for colorectal cancer screening at the time of hospital discharge and to advise them about the appropriate performance of the FOBT at home.

An audit of the utility of in-patient fecal occult blood testing.

Recent surveys of physician practice have suggested the existence of excessive, inappropriate use of the fecal occult blood test (FOBT). We studied the implementation of this test in hospitalized patients. We performed a retrospective chart review of 1000 randomly selected patients who had been discharged from the Medicine service at four teaching hospitals. Patient demographics, clinical presentation, presence or absence of overt GI bleeding, and use of medications that might affect the FOBT were recorded. Reviewers assessed whether patients who had FOBT would have been candidates for colon resection if asymptomatic colon cancer had been found. Digital rectal examination was documented in 44.8% of patients; the findings were recorded in only 9%. A total of 421 patients had FOBT on admission, usually on stool obtained at digital rectal examination. Of the patients with a positive FOBT, 17% had active GI bleeding. Only 41.1% of patients with a positive FOBT were referred to the gastroenterology service. In 70.5% of patients, FOBT could be considered inappropriate because of factors such as age, active GI bleeding, or use of aspirin or other nonsteroidal anti-inflammatory drugs. The FOBT, which is validated only for colorectal cancer screening, is often performed inappropriately in patients admitted to the hospital. This test should be restricted in hospital practice. It would be preferable to identify patients who are appropriate candidates for colorectal cancer screening at the time of hospital discharge and to advise them about the appropriate performance of the FOBT at home.

Value of Flexible Sigmoidoscopy

We would like to commend Dinning and colleagues 1 for their recent article regarding the prevalence of distal colonic neoplasia in patients with proximal lesions. This is an important issue meriting exploration, but we are concerned that some of their conclusions could be easily misapplied. No one questions the need for colonoscopy in evaluating symptomatic patients; in this group, it is clear that the entire colon should be visualized. Patients presenting for screening, however, are, by definition, symptom free. If one assumes a prevalence of asymptomatic colon cancer in the population of 1% (which may be high) and a false-positive rate of 10% for 60-cm screening flexible sigmoidoscopy, even missing 25% of lesions still yields a negative-predictive value of 99.7%. Therefore, an asymptomatic patient who has a negative value of screening flexible sigmoidoscopy has only a 0.3% chance of harboring a significant lesion, not the 25% chance as could be interpreted

The solitary cutaneous metastasis of asymptomatic colon cancer to an operative scar

Although umbilical or cutaneous metastases from asymptomatic internal malignancies are occasionally documented, the literature contains no report of a solitary cutaneous metastasis to an old operative scar from an asymptomatic internal malignancy. A rare case of colonic cancer presenting as a solitary subcutaneous metastasis to a lower abdominal scar resulting from an open prostatectomy is described in this communication. It was impossible to distinguish this subcutaneous metastasis from a pyogenic granuloma caused by residual sutures without histological evidence. Thus, a granuloma that persists despite repeated treatment may be a possible sign of asymptomatic internal malignancy.

Preoperative barium contrast enema in patients with inguinal hernia.

Whether patients over age 40 should have a barium contrast enema (BCE) examination for possible identification of an unsuspected colon carcinoma before elective inguinal herniorrhaphy remains an unanswered question. We reviewed the medical records of all patients over age 40 who had inguinal herniorrhaphy at our institution between January 1980 and December 1984. Of 80 patients, 46 received a preoperative barium enema. One asymptomatic colon carcinoma (2.1%) was discovered. The reported incidence of asymptomatic colon cancer found by BCE in association with inguinal hernia ranges from 0 to 2.5%. We conclude that if there is a cause and effect relationship between asymptomatic colon cancer and inguinal hernia, the mechanism is as yet unknown.

Analysis of asymptomatic colon cancer Tateshi

Analysis of asymptomatic colon cancer Tateshi

Occult blood testing for detection of asymptomatic colon cancer.

Twelve cases of “silent” colon cancer were analyzed. With one exception all had at least one of three stool specimens which was guaiac-positive. To facilitate multiple stool testing, we made use of commercially available guaiac-impregnated slides. Most of the patients followed a meat-free high residue diet during the 4-day period of stool collection. In a 3Vi-year period, over 900 routine adult patients were tested. Five per cent were guaiac-positive, and they were each given a barium enema examination. One per cent of the entire group proved to have asymptomatic colon cancer; two per cent had diverticulosis, and one per cent had non-malignant polyps. We believe that every adult should have this screening test annually.